Investor Relations

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

Inhibitor Therapeutics is a publicly traded, clinical stage pharmaceutical development company. We have a focus on developing and commercializing innovative therapies, using repurposed, already approved API’s (active pharmaceutical ingredients) that have clinical value and are patent protected. We have a significant amount of owned intellectual property around the use of itraconazole in oncology indications, especially in the treatment of Basal Cell Carcinoma Nevus Syndrome and both lung and prostate cancers.

Stock Snapshot

IR Contacts


Inhibitor Therapeutics, Inc.
900 W Platt St
Suite 200
Tampa, FL 33606

Investor Relations

Inhibitor Therapeutics, Inc.
Simon Bettink
VP of Operations

Transfer Agent

Laura Holson
PO Box 500
Newark, NJ 07101
T: (800) 937-5449

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.